Press Release

Article

Camber Pharmaceuticals Launches Chlorzoxazone Tablets, USP

Key Takeaways

  • Chlorzoxazone Tablets, USP, target relief from acute, painful musculoskeletal conditions as an adjunct therapy.
  • The tablets are intended to complement rest, physical therapy, and other treatment measures.
SHOW MORE

Camber Pharmaceuticals is excited to announce the addition of Chlorzoxazone Tablets, USP.

Chlorzoxazone Tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.

Chlorzoxazone 250 mg Tablets, USP are available in 60 count bottles.

To find out more information on Chlorzoxazone Tablets, USP, please visit: www.camberpharma.com/chlorzoxazone

Related Videos
Related Content
Camber Pharmaceuticals Launches Lurasidone Hydrochloride Tablets
April 14th 2025

Camber Pharmaceuticals Launches Lurasidone Hydrochloride Tablets

Site Logo
April 4th 2025

Camber Pharmaceuticals Announces Addition of Sodium Sulfate, Potassium Sulfate, and Magnesian Sulfate Oral Solution

Irosolv product shot -- Image credit: © IBSA USA
March 4th 2025

IBSA USA Expands its IBSA Care Line of Dietary Supplements With IROSOLV™

Site Logo
February 27th 2025

CVS Pharmacy® introduces enhanced flu testing and treatment offerings

Site Logo
February 6th 2025

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

Camber Pharmaceuticals Announces Addition of Sirolimus Oral Solution
January 29th 2025

Camber Pharmaceuticals Announces Addition of Sirolimus Oral Solution